Search results

53 results

• NEWSROOM

  TGA regulatory approval for Jorveza 0.5mg orally disintegrating tablets

  Dr. Falk Pharma Australia is pleased to announce we have received TGA regulatory approval for Jorveza^® 0.5mg orally disintegrating budesonide tablet - indicated "for the treatment of…
• Reporting Suspected Misconduct

  Misconduct Homepage Reporting Suspected Misconduct Reporting Suspected Misconduct Reports concerning actual or suspected misconduct can be given via our reporting system - also anonymously: File a…
• News

  NEWS Homepage News News On this page find all the latest news, events and activities that involves Dr. Falk Pharma. All categories Corporate Press release Study Indication Event
• NEWSROOM

  Back To The Future #2 – Advancing the plot with established therapies

  Symposium on 19.02.2026 during the Congress of ECCO in Stockholm